Hyperthermia in Clinical Oncology
H.S . Reinhold and J. Overgaard THE CLINICAL application of hyperthermia has a strong biological rationale [l-3] . Experimental and clinical studies indicate that tumour control rates can be significantly enhanced if, for example, radiation therapy is combined with hyperthermia [4, 51. If a tumour is heated one or more times to a temperature of 43°C or higher for an hour, the probability of response or permanent control increases substantially.
Nevertheless, some important problems remain. After about 15 years of experiments and technological developments in heat delivery and temperature measurement, it is clear that the application of a hyperthermic dose of sufficient intensity to a tumour is not simple. In the past the tumour temperature was measured with one thermocouple several times to give the "tumour temperature". Nowadays continuous multipoint thermometry is available, which indicates that it is not justified to speak about the tumour temperature but rather about a distribution of temperatures, which is heterogeneous not only in tumour space but also in treatment time. Apart from these technological developments, a serious concern was whether currently used experimental tumour systems are of any value for clinical research in hyperthermia (ref. effect, as well as the sequence and interval between the modalities, is much discussed [23] . No consensus was reached at the meeting, other than that the treatment should be at a sufficiently high temperature (preferably 43°C) and last for about an hour. An encouraging observation is that all the retrospective analyses of superficial hyperthermia (e.g. carcinoma of the breast and recurrences of this tumour [4, 241 and head and neck nodes) indicate that with increasing hyperthermia treatment level, significantly higher response rates are obtained [6, 7, 251 . In addition, some prolonged complete responses in pelvic chondrosarcoma were reported by the paediatric oncology service in Paris. The current indications for successful adjuvant deep hyperthermia are found mainly in sarcomas [6, 24-261 and abdominal carcinomas, especially those of the cervix, colon and rectum [24] . There is also a need to improve the present results in bladder carcinoma [27] . In addition, an increasing number of encouraging results with thermochemotherapy, applied regionally or with perfusion, are being reported [ 171. The meeting emphasized that hyperthermia is finding a definite place in the treatment of cancer.
As regards assessing the impact of hyperthermia on health care, a prospective cost-benefit analysis is being done by the Department of Economics at Erasmus University, Rotterdam, based on the results from the Rotterdam phase III trial on loco-regional hyperthermia plus radiotherapy. Such analysis is important: determining the value of a new, cost-increasing treatment modality [28] . Preliminary findings suggest that for pelvic tumours the costs may be moderate (about 1800 ECU per life year saved).
The meeting emphasized that deep heating for the treatment of pelvic malignancies has become feasible, and that the results are encouraging. The Rotterdam phase III trial with the BSD-2000 machine has been started to identify whether addition of this treatment will be of real benefit. 
